Pelotonia awards six grants to Ohio State

PELOTONIA awarded six, two-year grants to projects at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute.

Pelotonia is a fundraising bicycle tour established in 2009 to raise money for cancer research at Ohio State. In the past four years, 67 OSUCCC – James research teams have received Pelotonia Idea Grants. A total of $650,000 will be awarded in this latest round of grants, with $6.6 million in funding awarded since the program’s inception.

The 2014 Pelotonia Idea Grants funded the following projects: Identifying and Developing New Immunoagents for Cancer Diagnosis and Therapy; Proteasomal Pathway Regulates PTEN Protein Degradation and Promotes Carcinogenesis; A Mass-Spectrometry Approach to Mapping Histone Modification Crosstalk; Develop IL-27 Based Combinational Immunotherapy of Cancer; Ceragenin-based Therapy for Multiple Myeloma; and Defining the Role of Autophagy in Anoikis Resistance and in Peritoneal Carcinomatosis/Sarcomatosis.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.

October 22, 2025

Vol.51 No.38

Clinical Regulatory News Trials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).

October 17, 2025

Vol.51 No.38

By Edison T. Liu

News Analysis Regulatory News

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter and Jacquelyn Cobb

Guest Editorial

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

When the idea of looking at cancer center funding and the cancer burden of cancer center catchment areas came to us in the summer of 2024, we lived in a different context.

October 17, 2025

Vol.51 No.38

By Todd Burus, Caree McAfee and Pamela C. Hull

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.

October 17, 2025

Vol.51 No.38

By Heather Hampel and David W. Craig

Cancer Policy

Dems push GOP to extend ACA credits as part of a deal to end the government shutdown

Millions of Americans with Affordable Care Act marketplace health insurance will face higher costs next year if Congress doesn’t extend enhanced premium tax credits that have made the plans more affordable for low- and middle-income enrollees.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter

Pelotonia awards six grants to Ohio State

YOU MAY BE INTERESTED IN

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

Why both somatic and germline genomic profiling are essential for precision oncology

Dems push GOP to extend ACA credits as part of a deal to end the government shutdown

Renew today!

Subscriber content

Never miss an issue!

Login

Pelotonia awards six grants to Ohio State

YOU MAY BE INTERESTED IN

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

Why both somatic and germline genomic profiling are essential for precision oncology

Dems push GOP to extend ACA credits as part of a deal to end the government shutdown

Never miss an issue!

Login

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough